 NEW YORK, April 15, 2021 GLOBE NEWSWIRE -- GBS, Inc. NasdaqGS: GBS, a life sciences company developing non-invasive, real-time point-of-care POC diagnostic tests, and the Wyss Institute for Biologically Inspired Engineering at Harvard University Wyss Institute have received approval from the Harvard Longwood campus Institutional Review Board IRB to commence a validation study to test clinical samples from a COVID-19 repository. 